Image de couverture de Discovery Loop

Discovery Loop

Discovery Loop

De : Pharmatica
Écouter gratuitement

La meilleure offre de la saison | 0,99 €/mois pendant les 3 premiers mois + 15 € de crédit Audible

6,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
À propos de ce titre
Discovery Loop explores AI-driven discovery, lead optimisation, biomarkers, translational science, lab automation, rare disease research, next-generation modalities and the decisions shaping how new therapies are identified and advanced.Copyright 2026 Pharmatica Hygiene & gesundes Leben Wissenschaft
épisodes
  • Could Biological Ageing Be the Next Big Shift in Drug Discovery?
    31 Jul 2026
    In this special Scientific Council Spotlight episode of The Discovery Loop podcast, host Shubhangi Dua, Journalist, Podcast Producer and Podcast Host at Pharmatica.io, sits down with Deepankar Nayak, the CEO of Deep Longevity. Nayak also serves on Pharmatica’s Scientific Council.Together, the speakers on this pharma podcast unpack the true potential of biological ageing and why pharmaceutical leaders need to pay attention to the new research on longevity.They also talk about the industry-wide shift from talking about reactive disease treatment to proactively targeting ageing as a modifiable biological process.“The top-line message would be that we should all look at ageing like a modifiable biological process, rather than an inevitable consequence of getting older,” the CEO of Deep Longevity stated.For context, he added that researchers around the globe are attempting to study longevity using a platform so they could come up with innovations. These longevity-driven innovations aim to help people live longer, live healthier, as against trying to react to disease conditions.Also Read: Could Biological Age Become Pharma's Most Important Biomarker?What is AI-Driven Biological Ageing Important?When we talk about innovations in the enterprise space, AI cannot be dismissed. Nayak spotlights AI-driven biological ageing clocks that are developing or could be developed as a critical solution in clinical trials.AI-backed biological ageing clocks can serve as surrogate endpoints that can accelerate drug development and improve patient stratification.“If you are trying to demonstrate longevity intervention, you really don't have the luxury of running a 40-year-old clinical trial,” Nayak expresses to Dua on The Discover Loop episode.“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve the clinical trials,” he added. “We [Deep Longevity] created the technology that turns complex biological data into a quantitative measure of biological age and at the rate at which someone is ageing.”This is where Deep Longevity’s pharmaceutical technology comes into play. The enterprise enables the entire longevity ecosystem through biological ageing clocks.Also Read: Anthropic’s Big AI Drug Discovery AnnouncementHow Deep Longevity Helps in Developing Therapeutics for PharmaceuticalsDeep Longevity is a preventive health AI-driven company focusing on developing therapeutics. They also use digital interventions to improve health and longevity through their products and through the ageing clocks.In the field of longevity, pharma companies are looking to develop drugs or develop innovative diagnostics; others are running smarter clinical trials. However, in Deep Longevity, the task is to provide measurement and analytical technology to aid all of the above efforts.By turning complex biological data into a quantitative measure of biological age, the platform provides researchers a much faster readout of whether an intervention is changing the underlying biology.“Pharma industries use these clocks to identify patients who are biologically ageing the fastest and therefore may benefit most from a certain therapy,” Nayak tells Dua. “This will help in patient recruitment.”Those in the industry can track the trials and see if these trials are actually making meaningful progress early in the lifecycle.In case of no progress, the platform data can be used to help make adjustments to the trial protocol. For instance, researchers can use biological age predictions as a way to address individual treatments by adjusting the dosage of drugs and transform trials into “truly adaptive clinical trials.”“It’s a bold claim; however, I believe when deployed adequately, researchers can use biological age to even terminate programmes that are not showing the desired benefit,” Nayak tells Dua. As a result, pharma companies sponsoring or running clinical research programmes can “save millions of dollars in the process.”“That money can be saved and reinvested in their R&D programmes.”Ultimately, the conversation goes from talking about popular "biohacking" trends such as GLP-1 drugs and the need for evidence-based interventions, to urging pharma leaders to integrate biological ageing into their R&D strategies now to secure a competitive advantage in the coming decade.TakeawaysAgeing should be viewed as a modifiable biological process.Biological age is a better predictor of health outcomes than chronological age.GLP-1 medications are evolving from diabetes treatments to broader metabolic health solutions.Strength training is essential for health, especially in older adults.Caution is necessary when adopting new health trends and medications.Biological ageing clocks can transform clinical trials and patient care.Pharma leaders should start integrating biological ageing into their strategies now.The future of drug discovery will increasingly rely on biological ageing ...
    afficher plus Afficher moins
    26 min
  • Is AI Quietly Creating a GDPR Crisis in Clinical Research?
    17 Jul 2026
    Ask Diana Andrade what keeps global pharma compliance teams up at night, and she doesn't start with regulation. Instead, she addresses a misunderstanding."The biggest gap and risk," she says, is the assumption that key-coded, pseudonymised patient data is not personal data at all. People think it’s therefore safe to use in AI tools without caution. That’s in fact a misconception.In an industry quickly adopting generative AI for tasks from protocol drafting to drug discovery, this misunderstanding is becoming one of the costliest compliance oversights in clinical research.In the recent episode of The Discovery Loop podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io, sat down with Diana Andrade, Founder & Managing Director at RD Privacy and Data Protection Officer (DPO) for Biopharma and Life Sciences. They talk about the current state of data protection regulations and how enterprises can innovate responsibly.As the founder and lead at RD Privacy, Andrade serves as a data protection officer for biopharma and life sciences companies dealing with GDPR compliance, cross-border data transfers, and privacy governance across several jurisdictions.Her career began in contracts at the contract research organisation (CRO) giant PPD clinical research business of Thermo Fisher Scientific. Eventually, she moved into privacy law, revealing a gap where many lawyers understood data protection, but few knew enough about clinical research to apply it correctly.Also Read: 11 Clinical Trials Defining Pharmaceutical Strategy in 2026What’s the AI Misconception Costing Pharma CompaniesOn the Pharmatica podcast with Dua, Andrade spotlighted two key AI misunderstandings she frequently sees among sponsors and CROs.The first is technical. Teams confuse pseudonymization with anonymisation. Data that has been key-coded, stripped of clear identifiers but still traceable to an individual, is still considered personal data under GDPR. Using it in an AI tool does not change this classification, regardless of how the data is labelled internally.The second is cultural and arguably more dangerous. Compliance teams are beginning to think AI can handle compliance on its own. "It's very hard with AI," Andrade says. AI adoption will continue to rise, and familiarity with these tools is now essential in the industry. However, this increases the need for strong governance.Pharma enterprises still require major human oversight to establish guidelines and oversee AI's actions.In practice, this requires internal processes defining how AI can be used and active human oversight of every output. Andrade told Dua that you can’t trust everything AI produces without verifying it first.Where AI Has Earned Its Place in Clinical ResearchAndrade acknowledges significant value in AI tech across the clinical trial lifecycle. For instance, AI’s benefits include faster drafting of clinical research protocols, developing internal procedures that help smaller biopharma teams scale without increasing headcount, and analysing trial data for new drug development leads.However, the RD Privacy Managing Director is wary of using AI without supervision. She noted that each of these use cases involves feeding an AI system with sensitive material from business-confidential information and personal data, despite the data being key-coded. This combination is why she argues that pharma compliance programs must go beyond GDPR and specifically address emerging AI regulations, rather than treating these as separate issues.Why Every Pharma Company Needs a Dedicated DPO?Andrade advises pharma leaders that every biopharma enterprise needs a data protection officer or someone specifically responsible for its global privacy program, no matter its size.The reason is the structure of clinical trials, which can’t be contained in one country. They start in one controlled area and then expand rapidly. The legal basis for processing patient data can entirely change when moving from one country to another. In some markets, patient consent is necessary; in others, the sponsor's legal obligations and legitimate interests come into play, needing a documented legitimate interest assessment to ensure these interests do not violate patients' rights.Andrade believes that while compliance may come across as a puzzle, it can be managed with one piece but becomes exponentially harder as trials move into new markets. Each new country adds pieces that must fit together. Without a DPO to manage this puzzle, she warns, "very quickly your clinical trial can become a mess."She emphasises that the DPO role should be viewed as an ongoing necessity, not a one-time task. It's not about filing documentation away and forgetting it; it requires active involvement that evolves with clinical operations and needs support from every growing team within the organisation.Also Watch: AI in Pharma: Hype vs. What Actually WorksHow to Stay Up-to-Date in Pharma Regulatory SpaceTo...
    afficher plus Afficher moins
    29 min
  • Why Drug Discovery Breakthroughs Are Failing to Reach Patients
    4 Jun 2026
    Drug discovery has never moved faster. The tools available to researchers today, from AI-assisted molecular screening to advanced nanotechnology platforms, have dramatically compressed timelines that once took decades. Despite this acceleration, a troubling pattern persists, and that is most innovations developed in the laboratory never reach the patients who actually need them.In this episode of Discovery Loop, host Trisha Pillay sits down with Christian Nkanga, Chief Scientific Officer at Memsel, to examine why the gap between scientific discovery and clinical reality remains so wide. They also covered what the pharmaceutical industry must do differently to close it.Science Is Moving Faster Than the System Can HandleNkanga's perspective on this problem is shaped by more than professional expertise. As both a professor and a practising chief scientist, he has worked directly with diseases for which no adequate treatment exists. That experience gives his analysis a clarity that purely academic commentary rarely achieves. His starting point is a statistic that deserves more attention than it typically receives. Between 2000 and 2019, approximately two million publications were produced on nanotechnology. Of those, roughly 80 products received FDA approval. Two million studies, but only 80 approved products.The science, Nkanga argues, is not the problem. The problem is the system through which that science must travel to reach patients. Regulatory requirements, safety validation, reproducibility standards, manufacturing scale-up, and quality management all stand between a laboratory result and a licensed therapy. Each stage creates another point where promising research can stall. The challenge for pharmaceutical professionals is not to dismiss these requirements. They exist for good reason. The challenge is to understand them early enough to design research programmes that can actually survive contact with them.Documentation, Reproducibility, and the Trust Regulatory Agencies RequireNkanga is equally direct about the internal practices that separate successful development programmes from those that fail to progress. Effective documentation and reproducibility are not bureaucratic obligations. They are the foundation on which regulatory trust is built. Regulatory agencies cannot approve what they cannot verify. When a research team submits data to support a clinical application, the quality of that documentation, its completeness, its consistency, and its internal coherence communicate something essential about the rigour of the science behind it.Teams that treat documentation as an afterthought, to be assembled retrospectively once the scientific work is complete, consistently find themselves unable to satisfy the evidentiary standards that approval requires. Reproducibility carries the same weight. If a result cannot be replicated under defined conditions, it cannot form the basis of a product that will be manufactured at scale and administered to patients. Building reproducibility into research design from the outset, rather than hoping it emerges naturally, is one of the clearest predictors of whether a programme will survive into later development stages.Translational Development as a DisciplineThe broader argument running through this conversation is that translational development, the process of moving science from experimental success to clinical application, needs to be treated as a distinct and rigorous discipline in its own right. It is not a natural extension of good research. It requires a different set of skills, a different set of questions, and a different understanding of what success looks like.For pharmaceutical professionals, that means building translational thinking into programmes from day one. It means asking not only whether a compound works in a controlled setting, but whether the evidence generated is sufficient to persuade a regulator, manufacturable at a viable cost, and relevant to the clinical problem it claims to solve. The patients waiting for those innovations do not have the luxury of waiting for the industry to work this out incrementally. The science is ready. The question is whether the systems, practices, and disciplines needed to translate it are ready too. For more pharmaceutical science and drug discovery insights, visit Memsel or connect with the guest:Christian Nkanga: LinkedIn | Chief Scientific Officer, MemselTakeawaysInnovation in drug discovery is accelerating, but real-world impact is limited.Only a small fraction of scientific knowledge translates into marketable products.Pre-research phases are critical and often underestimated in drug development.Successful programs focus on scalability and reproducibility from the start.Outsourcing non-core functions can help small companies focus on innovation.Good documentation practices are essential for regulatory approval and reproducibility.Engaging end-users early in the process is vital for successful product ...
    afficher plus Afficher moins
    30 min
adbl_web_anon_alc_button_suppression_t1
Aucune critique pour le moment